Harmful effects of functional hypercortisolism: A working hypothesis

Endocrine

Volumn 46, Issue 3, 2014, Pages 370-386

  Tirabassi, Giacomo ^a   Boscaro, Marco ^a   Arnaldi, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Cushing's syndrome; Functional hypercortisolism; Pseudo Cushing state; Systemic complications

Indexed keywords

ALCOHOLISM; ANOREXIA NERVOSA; BULIMIA; CUSHING DISEASE; CUSHINGOID SYNDROME; DIABETES MELLITUS; DISEASE SEVERITY; END STAGE RENAL DISEASE; ENDOCRINE DISEASE; FUNCTIONAL HYPERCORTISOLISM; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SHIFT WORKER; SKIN ATROPHY; SKIN BRUISING; STRIA; CUSHING SYNDROME; DIFFERENTIAL DIAGNOSIS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; SEVERITY OF ILLNESS INDEX;

CUSHING SYNDROME; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; SEVERITY OF ILLNESS INDEX;

EID: 84904555694     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0112-y     Document Type: Review

References (189)

1. C. Tsigos, G.P. Chousos, Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 53, 865-871 (2002)
2. G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications. J. Endocrinol. Invest. 35, 434-448 (2012)
3. G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593-5602 (2003)
4. G. Arnaldi, G. Tirabassi, R. Papa, G. Furlani, L. Trementino, M. Cardinaletti, E. Faloia, M. Boscaro, Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing's disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. Eur. J. Endocrinol. 160, 891-898 (2009)
5. G. Tirabassi, E. Faloia, R. Papa, G. Furlani, M. Boscaro, G. Arnaldi, Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing's disease. J. Clin. Endocrinol. Metab. 95, 1115-1122 (2010)
6. G. Tirabassi, R. Papa, E. Faloia, M. Boscaro, G. Arnaldi, Cor-ticotrophin- releasing hormone and desmopressin tests in the differential diagnosis between Cushing's disease and pseudo- Cushing state: a comparative study. Clin. Endocrinol. (Oxf) 75, 666-672 (2011)
7. L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526-1540 (2008)
8. S.A. Doi, J. Clark, A.W. Russell, Concordance of the late night salivary cortisol in patients with Cushing's syndrome and elevated urine-free cortisol. Endocrine 43, 327-333 (2013)
9. H. Raff, Update on late-night salivary cortisol for the diagnosis of Cushing's syndrome: methodological considerations. Endocrine 44, 346-349 (2013)
10. H. Raff, Salivary cortisol and the diagnosis of Cushing's syndrome: a coming of age. Endocrine 41, 353-354 (2012)
11. Z.E. Belaya, A.V. Iljin, G.A. Melnichenko, L.Y. Rozhinskaya, N.V. Dragunova, L.K. Dzeranova, S.A. Butrova, E.A. Troshina, I.I. Dedov, Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing's syndrome. Endocrine 41, 494-500 (2012)
12. C.A. Carrasco, M. García, M. Goycoolea, J. Cerda, J. Bertherat, O. Padilla, D. Meza, N. Wohllk, T. Quiroga, Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing's syndrome using an automated immunoassay system. Endocrine 41, 487-493 (2012)
13. M.D. Sullivan, P. O'Connor, P. Feeney, D. Hire, D.L. Simmons, D.W. Raisch, L.J. Fine, K.M. Narayan, M.K. Ali, W.J. Katon, Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care 35, 1708-1715 (2012)
14. M.S. Player, L.E. Peterson, Anxiety disorders, hypertension, and cardiovascular risk: a review. Int. J. Psychiatry Med. 41, 365-377 (2011)
15. H. Teede, A. Deeks, L. Moran, Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41 (2010)
16. A. Pan, N. Keum, O.I. Okereke, Q. Sun, M. Kivimaki, R.R. Rubin, F.B. Hu, Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 35, 1171-1180 (2012)
17. C. Gragnoli, Depression and type 2 diabetes: cortisol pathway implication and investigational needs. J. Cell. Physiol. 227, 2318-2322 (2012)
18. D. Kopf, S. Westphal, C.W. Luley, S. Ritter, M. Gilles, B. Weber- Hamann, F. Lederbogen, H. Lehnert, F.A. Henn, I. Heuser, M. Deuschle, Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J. Clin. Psychopharmacol. 24, 527-531 (2004)
19. Z. Rihmer, M. Arató, Depression and diabetes mellitus. A study of the relationship between serum cortisol and blood sugar levels in patients with endogenous depression. Neuropsychobiology 8, 315-318 (1982)
20. B. Weber-Hamann, F. Hentschel, A. Kniest, M. Deuschle, M. Colla, F. Lederbogen, I. Heuser, Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom. Med. 64, 274-277 (2002)
21. G. Veen, E.J. Giltay, R.H. DeRijk, I.M. van Vliet, J. van Pelt, F.G. Zitman, Salivary cortisol, serum lipids, and adiposity in patients with depressive and anxiety disorders. Metabolism 58, 821-827 (2009)
22. B. Pfohl, M. Rederer, W. Coryell, D. Stangl, Association between post-dexamethasone cortisol level and blood pressure in depressed inpatients. J. Nerv. Ment. Dis. 179, 44-47 (1991)
23. N. Vogelzangs, K. Suthers, L. Ferrucci, E.M. Simonsick, A. Ble, M. Schrager, S. Bandinelli, F. Lauretani, S.V. Giannelli, B.W. Penninx, Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology 32, 151-159 (2007)
24. S. Komatsu, M. Yamamoto, K. Arishima, Y. Eguchi, Maternal adrenocortical hormones maintain the early development of pancreatic B cells in the fetal rat. J. Anat. 193, 551-557 (1998)
25. J.N. Mann, J.H. Thakore, Melancholic depression and abdominal fat distribution: a mini-review. Stress 3, 1-15 (1999)
26. J.H. Thakore, P.J. Richards, R.H. Reznek, A. Martin, T.G. Dinan, Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol. Psychiatry 41, 1140-1142 (1997)
27. B.W. Penninx, A.T. Beekman, A. Honig, D.J. Deeg, R.A. Schoevers, J.T. van Eijk, W. van Tilburg, Depression and cardiac mortality: results from a community-based longitudinal study. Arch. Gen. Psychiatry. 58, 221-227 (2001)
28. M. Vythilingam, J. Chen, J.D. Bremner, C.M. Mazure, P.K. Maciejewski, J.C. Nelson, Psychotic depression and mortality. Am. J. Psychiatry 160, 574-576 (2003)
29. W. Coryell, J. Fiedorowicz, M. Zimmerman, E. Young, HPA-axis hyperactivity and mortality in psychotic depressive disorder: preliminary findings. Psychoneuroendocrinology 33, 654-658 (2008)
30. M.H. Kamphuis, Depression and cardiovascular disease: the role of diet, lifestyle and health (Gildeprint BV, Enschede (the Netherlands), 2006)
31. A.J. Broadley, A. Korszun, E. Abdelaal, V. Moskvina, J. Deanfield, C.J. Jones, M.P. Frenneaux, Metyrapone improves endothelial dysfunction in patients with treated depression. J. Am. Coll. Cardiol. 48, 170-175 (2006)
32. L.J. Siever, T.W. Uhde, New studies and perspectives on the noradrenergic receptor system in depression: effects of the alpha 2-adrenergic agonist clonidine. Biol. Psychiatry 19, 131-156 (1984)
33. A.J. Mitchell, T.R. Dening, Depression-related cognitive impairment: possibilities for its pharmacological treatment. J. Affect. Disord. 36, 79-87 (1996)
34. A.L. Byers, K. Yaffe, Depression and risk of developing dementia. Nat. Rev. Neurol. 7, 323-331 (2011)
35. F. Thomson, M. Craighead, Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochem. Res. 33, 691-707 (2008)
36. M.W. Strachan, R.M. Reynolds, B.M. Frier, R.J. Mitchell, J.F. Price, The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies. Diabetes Obes. Metab. 11, 407-414 (2009)
37. A.M. MacLullich, J.R. Seckl, Diabetes and cognitive decline: are steroids the missing link? Cell Metab. 7, 286-287 (2008)
38. P.E. Stokes, The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Eur. Neuropsychopharmacol. 5(Suppl 1), 77-82 (1995)
39. D.R. Rubinow, R.M. Post, R. Savard, P.W. Gold, Cortisol hypersecretion and cognitive impairment in depression. Arch. Gen. Psychiatry 41, 279-283 (1984)
40. J.K. Belanoff, M. Kalehzan, B. Sund, S.K. Fleming Ficek, A.F. Schatzberg, Cortisol activity and cognitive changes in psychotic major depression. Am. J. Psychiatry 158, 1612-1616 (2001)
41. B. Siegel, D. Gurevich, G.F. Oxenkrug, Cognitive impairment and cortisol resistance to dexamethasone suppression in elderly depression. Biol. Psychiatry 25, 229-234 (1989)
42. J. Wauthy, M. Ansseau, R. von Frenckell, C. Mormont, J.J. Legros, Memory disturbances and dexamethasone suppression test in major depression. Biol. Psychiatry 30, 736-738 (1991)
43. G. Winokur, D.W. Black, A. Nasrallah, DST nonsuppressor status: relationship to specific aspects of the depressive syndrome. Biol. Psychiatry 22, 360-368 (1987)
44. A. Georgotas, R.E. McCue, O.M. Kim, W.E. Hapworth, B. Reisberg, P.M. Stoll, E. Sinaiko, C. Fanelli, P.E. Stokes, Dexamethasone suppression in dementia, depression, and normal aging. Am. J. Psychiatry 143, 452-456 (1986)
45. D.A. Axelson, P.M. Doraiswamy, W.M. McDonald, O.B. Boyko, L.A. Tupler, L.J. Patterson, C.B. Nemeroff, E.H. Ellinwood Jr, K.R. Krishnan, Hypercortisolemia and hippocampal changes in depression. Psychiatry Res. 47, 163-173 (1993)
46. G. Cizza, P. Ravn, G.P. Chrousos, P.W. Gold, Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol. Metab. 12, 198-203 (2001)
47. G. Cizza, S. Primma, G. Csako, Depression as a risk factor for osteoporosis. Trends Endocrinol. Metab. 20, 367-373 (2009)
48. K.M. Yazici, A. Akinci, A. Sütçü, L. Ozçakar, Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res. 117, 271-275 (2003)
49. J.D. Amsterdam, M.B. Hooper, Bone density measurement in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 267-277 (1998)
50. D. Michelson, C. Stratakis, L. Hill, J. Reynolds, E. Galliven, G. Chrousos, P. Gold, Bone mineral density in women with depression. N. Engl. J. Med. 335, 1176-1181 (1996)
51. O. Altindag, A. Altindag, M. Asoglu, M. Gunes, N. Soran, Z. Deveci, Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int. J. Clin. Pract. 61, 416-420 (2007)
52. U. Halbreich, N. Rojansky, S. Palter, M. Hreshchyshyn, J.Kreeger, Y. Bakhai, R. Rosan,Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 57, 485-491 (1995)
53. F. Eskandari, P.E. Martinez, S. Torvik, T.M. Phillips, E.M. Sternberg, S. Mistry, D. Ronsaville, R. Wesley, C. Toomey, N.G. Sebring, J.C. Reynolds, M.R. Blackman, K.A. Calis, P.W. Gold, G. Cizza, Premenopausal, Osteoporosis Women, Alendronate, Depression (POWER) Study Group, Low bone mass in premenopausal women with depression. Arch. Intern. Med. 167, 2329-2336 (2007)
54. M.A. Tichomirowa, M.E. Keck, H.J. Schneider, M. Paez-Pereda, U. Renner, F. Holsboer, G.K. Stalla, Endocrine disturbances in depression. J. Endocrinol. Invest. 28, 89-99 (2005)
55. W. Pitchot, J. Reggers, E. Pinto, M. Hansenne, M. Ansseau, Catecholamine and HPA axis dysfunction in depression: relationship with suicidal behavior. Neuropsychobiology 47, 152-157 (2003)
56. E. Syvälahti, Dexamethasone suppression test and the levels of serum growth hormone, plasma vasopressin and plasma homovanillic acid in depressed in- and out-patients. Acta Psychiatr. Scand. 71, 105-110 (1985)
57. F. Contreras, J.M. Menchon, M. Urretavizcaya, M.A. Navarro, J. Vallejo, G. Parker, Hormonal differences between psychotic and non-psychotic melancholic depression. J. Affect. Disord. 100, 65-73 (2007)
58. K. O'Flynn, T.G. Dinan, Baclofen-induced growth hormone release in major depression: relationship to dexamethasone suppression test result. Am. J. Psychiatry 150, 1728-1730 (1993)
59. R.J. Dolan, S.P. Calloway, The human growth hormone response to clonidine: relationship to clinical and neuroendocrine profile in depression. Am. J. Psychiatry 143, 772-774 (1986)
60. F. Duval, M.C. Mokrani, J.P. Macher, Reply to letter to the editor. Psychoneuroendocrinology 32, 211-212 (2007)
61. S.D. Targum, A.C. Sullivan, S.M. Byrnes, Neuroendocrine interrelationships in major depressive disorder. Am. J. Psychiatry 139, 282-286 (1982)
62. C. Kirkegaard, B.J. Carroll, Dissociation of TSH adrenocortical disturbances in endogenous depression. Psychiatry Res. 3, 253-264 (1980)
63. M.P. Hage, S.T. Azar, The link between thyroid function and depression. J. Thyroid Res. (2012). doi:10.1155/2012/590648
64. M. Maes, M. Vandewoude, L. Maes, C. Schotte, P. Cosyns, A revised interpretation of the TRH test results in female depressed patients. Part I: TSH responses. Effects of severity of illness, thyroid hormones, monoamines, age, sex hormonal, corticosteroid and nutritional state. J. Affect. Disord. 16, 203-213 (1989)
65. H. Agren, L. Wide, TRH tests with analyses of TSH, prolactin, and GH responses in subtypes of patients with major depressive disorders. Acta Psychiatr. Scand. 73, 549-558 (1986)
66. L. Bartalena, G.F. Placidi, E. Martino, M. Falcone, L. Pellegrini, L. Dell'Osso, A. Pacchiarotti, A. Pinchera, Nocturnal serum thyrotropin (TSH) surge and the TSH response to TSH-releasing hormone: dissociated behavior in untreated depressives. J. Clin. Endocrinol. Metab. 71, 650-655 (1990)
67. A.J. Rush, D.E. Giles, M.A. Schlesser, P.J. Orsulak, J.E. Weissenburger, C.L. Fulton, C.J. Fairchild, H.P. Roffwarg, Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol. Psychiatry 41, 915-928 (1997)
68. E.A. Young, A. Korszun, The hypothalamic-pituitary-gonadal axis in mood disorders. Endocrinol. Metab. Clin. North Am. 31, 63-78 (2002)
69. S.N. Seidman, S.P. Roose, The relationship between depression and erectile dysfunction. Curr. Psychiatry Rep. 2, 201-205 (2000)
70. U. Schweiger, M. Deuschle, B. Weber, A. Körner, C.H. Lammers, J. Schmider, U. Gotthardt, I. Heuser, Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom. Med. 61, 292-296 (1999)
71. A. Steiger, U. von Bardeleben, K. Wiedemann, F. Holsboer, Sleep EEG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission. J. Psychiatr. Res. 25, 169-177 (1991)
72. R.T. Rubin, R.E. Poland, I.M. Lesser, Neuroendocrine aspects of primary endogenous depression VIII. Pituitary-gonadal axis activity in male patients and matched control subjects. Psychoneuroendocrinology 14, 217-229 (1989)
73. D.F. Swaab, A.M. Bao, P.J. Lucassen, The stress system in the human brain in depression and neurodegeneration. Ageing Res. Rev. 4, 141-194 (2005)
74. F. Petraglia, S. Sutton, W. Vale, P. Plotsky, Corticotropin-releasing factor decreases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophysial-portal circulation. Endocrinology 120, 1083-1088 (1987)
75. E.L. Perez, J. Blouin, A. Blouin, The dexamethasone suppression test in bulimia: nonsuppression associated with depression and suboptimal weight. J. Clin. Psychiatry 49, 94-96 (1988)
76. N. Piran, S. Kennedy, P.E. Garfinkel, M. Owens, Affective disturbance in eating disorders. J. Nerv. Ment. Dis. 173, 395-400 (1985)
77. E.A. Lawson, D. Donoho, K.K. Miller, M. Misra, E. Meenaghan, J. Lydecker, T. Wexler, D.B. Herzog, A. Klibanski, Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. J. Clin. Endocrinol. Metab. 94, 4710-4716 (2009)
78. K.R. Bruce, H. Steiger, M. Israël, P. Groleau, N.M. Ng Ying Kin, A.S. Ouellette, L. Sycz, G. Badawi, Cortisol responses on the dexamethasone suppression test among women with Buli-mia- spectrum eating disorders: associations with clinical symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 38, 241-246 (2012)
79. R.G. Laessle, M. Fischer, M.M. Fichter, K.M. Pirke, J.C. Krieg, Cortisol levels and vigilance in eating disorder patients. Psychoneuro-endocrinology 17, 475-484 (1992)
80. C. Lauer, W. Schreiber, M. Berger, K.M. Pirke, F. Holsboer, J.C. Krieg, The effect of neuroendocrine secretion on brain morphology and EEG sleep in patients with eating disorders. Eur. Arch. Psychiatry Neurol. Sci. 238, 208-212 (1989)
81. D.K. Katzman, E.K. Lambe, D.J. Mikulis, J.N. Ridgley, D.S. Goldbloom, R.B. Zipursky, Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa. J. Pediatr. 129, 794-803 (1996)
82. J. Castro-Fornieles, N. Bargalló, L. Lázaro, S. Andrés, C. Falcon, M.T. Plana, C. Junqué, A cross-sectional and follow-up voxel-based morphometric MRI study in adolescent anorexia nervosa. J. Psychiatr. Res. 43, 331-340 (2009)
83. G.D. Giordano, P. Renzetti, R.C. Parodi, L. Foppiani, F. Zandrino, G. Giordano, F. Sardanelli, Volume measurement with magnetic resonance imaging of hippocampus-amygdala formation in patients with anorexia nervosa. J. Endocrinol. Invest. 24, 510-514 (2001)
84. J.A. Seed, R.A. Dixon, S.E. McCluskey, A.H. Young, Basal activity of the hypothalamic-pituitary-adrenal axis and cognitive function in anorexia nervosa. Eur. Arch. Psychiatry Clin. Neurosci. 250, 11-15 (2000)
85. J. Jolles, Neuropeptides and cognitive disorders. Prog. Brain Res. 65, 177-192 (1986)
86. E.A. Lawson, A. Klibanski, Endocrine abnormalities in anorexia nervosa. Nat. Clin. Pract. Endocrinol. Metab. 4, 407-414 (2008)
87. J.R. Newton, C.P. Freeman, W.J. Hannan, S. Cowen, Osteoporosis and normal weight bulimia nervosa-which patients are at risk? J. Psychosom. Res. 37, 239-247 (1993)
88. S. Zipfel, M.J. Seibel, B. Löwe, P.J. Beumont, C. Kasperk, W. Herzog, Osteoporosis in eating disorders: a follow-up study of patients with anorexia and bulimia nervosa. J. Clin. Endocrinol. Metab. 86, 5227-5233 (2001)
89. F. Jacoangeli, A. Zoli, A. Taranto, F. Staar Mezzasalma, C. Ficoneri, S. Pierangeli, G. Menzinger, M.R. Bollea, Osteoporosis and anorexia nervosa: relative role of endocrine alterations and malnutrition. Eat. Weight. Disord. 7, 190-195 (2002)
90. B.M. Biller, V. Saxe, D.B. Herzog, D.I. Rosenthal, S. Holzman, A. Klibanski, Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J. Clin. Endocrinol. Metab. 68, 548-554 (1989)
91. K.A. Carmichael, D.H. Carmichael, Bone metabolism and osteopenia in eating disorders. Medicine (Baltimore) 74, 254-267 (1995)
92. M. Misra, R. Prabhakaran, K.K. Miller, M.A. Goldstein, D. Mickley, L. Clauss, P. Lockhart, J. Cord, D.B. Herzog, D.K. Katzman, A. Klibanski, Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. J. Clin. Endocrinol. Metab. 93, 1292-1297 (2008)
93. S. Naessén, K. Carlström, R. Glant, H. Jacobsson, A.L. Hirschberg, Bone mineral density in bulimic women-influence of endocrine factors and previous anorexia. Eur. J. Endocrinol. 155, 245-251 (2006)
94. ESHRE Capri Workshop Group, Nutrition and reproduction in women. Hum. Reprod. Update 12, 193-207 (2006)
95. U. Schweiger, K.M. Pirke, R.G. Laessle, M.M. Fichter, Gonadotropin secretion in bulimia nervosa. J. Clin. Endocrinol. Metab. 74, 1122-1127 (1992)
96. M. Misra, K.K. Miller, J. Bjornson, A. Hackman, A. Aggarwal, J. Chung, M. Ott, D.B. Herzog, M.L. Johnson, A. Klibanski, Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab. 88, 5615-5623 (2003)
97. R.K. Støving, J.D. Veldhuis, A. Flyvbjerg, J. Vinten, J. Hangaard, O.G. Koldkjaer, J. Kristiansen, C. Hagen, Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J. Clin. Endocrinol. Metab. 84, 2056-2063 (1999)
98. C. Bannai, N. Kuzuya, Y. Koide, T. Fujita, M. Itakura, K. Kawai, K. Yamashita, Assessment of the relationship between serum thyroid hormone levels and peripheral metabolism in patients with anorexia nervosa. Endocrinol. Jpn. 35, 455-462 (1988)
99. H. Tamai, N. Kobayashi, S. Fukata, Y. Hirota, S. Matsubayashi, T. Nakagawa, M.C. Okimura, R.M. Walter Jr, L.F. Kumagai, Paradoxical responses of plasma cortisol, adrenocorticotropic hormone and growth hormone to thyrotropin-releasing hormone and luteinizing-hormone-releasing hormone in anorexia nervosa patients. Psychother. Psychosom. 46, 147-151 (1986)
100. S. Grinspoon, L. Thomas, K. Miller, S. Pitts, D. Herzog, A. Klibanski, Changes in regional fat redistribution and the effects of estrogen during spontaneous weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 73, 865-869 (2001)
101. L. Mayer, B.T. Walsh, R.N. Pierson Jr, S.B. Heymsfield, D. Gallagher, J.Wang,M.K. Parides, R.L. Leibel,M.P.Warren, E. Killory,D. Glasofer, Body fat redistribution after weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 81, 1286-1291 (2005)
102. J. Balldin, U. Berggren, K. Bokström, G. Lindstedt, J. Sjöberg, C. Wendestam, Dexamethasone suppression test in alcohol withdrawal: relationship to depression and liver function. Drug Alcohol Depend. 30, 175-179 (1992)
103. M.T. Abou-Saleh, J. Merry, A. Coppen, Dexamethasone suppression test in alcoholism. Acta Psychiatr. Scand. 69, 112-116 (1984)
104. S.K. Majumdar, G.K. Shaw, P.K. Bridges, Relationship between plasma cortisol concentrations and depression in chronic alcoholic patients. Drug Alcohol Depend 14, 45-49 (1984)
105. A. Heinz, H. Weingartner, D. George, D. Hommer, O.M. Wolkowitz, M. Linnoila, Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations. Psychiatry Res. 89, 97-106 (1999)
106. N. Müller, M. Hoehe, H.E. Klein, G. Nieberle, H.P. Kapfhammer, F. May, O.A. Müller, M. Fichter, Endocrinological studies in alcoholics during withdrawal and after abstinence. Psychoneuroendocrinology 14, 113-123 (1989)
107. M. Huntgeburth, H. Ten Freyhaus, S. Rosenkranz, Alcohol consumption and hypertension. Curr. Hypertens. Rep. 7, 180-185 (2005)
108. J.F. Potter, L.T. Bannan, J.B. Saunders, M.C. Ingram, D.G. Beevers, Blood pressure and pressor mechanisms during alcohol withdrawal. J. Hypertens. Suppl. 1, 97-99 (1983)
109. L.T. Bannan, J.F. Potter, D.G. Beevers, J.B. Saunders, J.R. Walters, M.C. Ingram, Effect of alcohol withdrawal on blood pressure, plasma renin activity, aldosterone, cortisol and dopamine beta-hydroxylase. Clin. Sci. (Lond) 66, 659-663 (1984)
110. D.B. Maurel, N. Boisseau, C.L. Benhamou, C. Jaffre, Alcohol and bone: review of dose effects and mechanisms. Osteoporos. Int. 23, 1-16 (2012)
111. R.M. Couch, Dissociation of cortisol and adrenal androgen secretion in poorly controlled insulin-dependent diabetes mellitus. Acta Endocrinol. (Copenh.) 127, 115-117 (1992)
112. T.B. Kaye, R.A. Rubin, A.B. Goldfine, K. Rajamani, B.T. Kinsley, U.M. Vischer, D.C. Simonson, Effect of glycemic control on the overnight dexamethasone suppression test in patients with diabetes mellitus. J. Clin. Endocrinol. Metab. 74, 640-644 (1992)
113. J.I. Hudson, M.S. Hudson, A.J. Rothschild, L. Vignati, A.F. Schatzberg, J.C. Melby, Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus. Arch. Gen. Psychiatry 41, 1086-1089 (1984)
114. A.A. Mosbah, N.A. Abd-Ellatif, E.I. Sorour, Influence of serum cortisol levels on glycemic control in children with type 1 diabetes. J. Egypt Soc. Parasitol. 41, 777-784 (2011)
115. G. Valsamakis, A. Anwar, J.W. Tomlinson, C.H. Shackleton, P.G. McTernan, R. Chetty, P.J. Wood, A.K. Banerjee, G. Holder, A.H. Barnett, P.M. Stewart, S. Kumar, 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89, 4755-4761 (2004)
116. S.B. Abraham, D. Rubino, N. Sinaii, S. Ramsey, L.K. Nieman, Cortisol, obesity and the metabolic syndrome: a cross-sectional study of obese subjects and review of the literature. Obesity 21, 105-117 (2013)
117. K.M. Oltmanns, B. Dodt, B. Schultes, H.H. Raspe, U. Schweiger, J. Born, H.L. Fehm, A. Peters, Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur. J. Endocrinol. 154, 325-331 (2006)
118. E. Rask, B.R. Walker, S. Söderberg, D.E. Livingstone, M. Eliasson, O. Johnson, R. Andrew, T. Olsson, Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity. J. Clin. Endocrinol. Metab. 87, 3330-3336 (2002)
119. R.S. Lindsay, D.J. Wake, S. Nair, J. Bunt, D.E. Livingstone, P.A. Permana, P.A. Tataranni, B.R. Walker, Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 88, 2738-2744 (2003)
120. L.L. Gathercole, P.M. Stewart, Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J. Steroid Biochem. Mol. Biol. 122, 21-27 (2010)
121. R.C. Andrews, O. Rooyackers, B.R. Walker, Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 285-291 (2003)
122. M. Hawkins, D. Hunter, P. Kishore, S. Schwartz, M. Hompesch, G. Hollis, R. Levy, B. Williams, R. Huber, INCB013739, a selective inhibitor of 11b-hydroxysteroid dehydrogenase type 1 (11bHSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus. Diabetes 57(Suppl 1), A99-A100 (2008). (Abstract 1)
123. R.M. Reynolds, J. Labad, M.W. Strachan, A. Braun, F.G. Fowkes, A.J. Lee, B.M. Frier, J.R. Seckl, B.R. Walker, J.F. Price, Edinburgh Type 2 Diabetes Study (ET2DS) Investigators, Elevated fasting plasma cortisol is associated with ischemic heart disease and its risk factors in people with type 2 diabetes: the Edinburgh type 2 diabetes study. J. Clin. Endocrinol. Metab. 95, 1602-1608 (2010)
124. M. Peppa-Patrikiou, M. Scordili, A. Antoniou, M. Giannaki, M. Dracopoulou, C. Dacou-Voutetakis, Carotid atherosclerosis in adolescents and young adults with IDDM. Relation to urinary endothelin, albumin, free cortisol, and other factors. Diabetes Care 21, 1004-1007 (1998)
125. C. Dacou-Voutetakis, M. Peppa-Patrikiou, M. Dracopoulou, Urinary free cortisol and its nyctohemeral variation in adolescents and young adults with IDDM: relation to endothelin 1 and indices of diabetic angiopathy. J. Pediatr. Endocrinol. Metab. 11, 437-445 (1998)
126. I. Chiodini, G. Adda, A. Scillitani, F. Coletti, V. Morelli, S. Di Lembo, P. Epaminonda, B. Masserini, P. Beck-Peccoz, E. Orsi, B. Ambrosi, M. Arosio, Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 30, 83-88 (2007)
127. A.M. Stranahan, T.V. Arumugam, R.G. Cutler, K. Lee, J.M. Egan, M.P. Mattson, Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 11, 309-317 (2008)
128. H. Bruehl, O.T. Wolf, V. Sweat, A. Tirsi, S. Richardson, A. Convit, Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res. 1280, 186-194 (2009)
129. R.M. Reynolds, M.W. Strachan, J. Labad, A.J. Lee, B.M. Frier, F.G. Fowkes, R. Mitchell, J.R. Seckl, I.J. Deary, B.R. Walker, J.F. Price, Edinburgh Type 2 Diabetes Study Investigators, Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 33, 714-720 (2010)
130. T.C. Sandeep, J.L.Yau, A.M.MacLullich, J.Noble, I.J.Deary,B.R. Walker, J.R. Seckl, 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. USA 101, 6734-6739 (2004)
131. M. Duong, J.I. Cohen, A. Convit, High cortisol levels are associated with low quality food choice in type 2 diabetes. Endocrine 41, 76-81 (2012)
132. M. Christ-Crain, B. Kola, F. Lolli, C. Fekete, D. Seboek, G. Wittmann, D. Feltrin, S.C. Igreja, S. Ajodha, J. Harvey-White, G. Kunos, B. Müller, F. Pralong, G. Aubert, G. Arnaldi, G. Giacchetti, M. Boscaro, A.B. Grossman, M. Korbonits, AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 22, 1672-1683 (2008)
133. H. Djursing, H.C. Nyholm, C. Hagen, L. Carstensen, L.M. Pedersen, Clinical and hormonal characteristics in women with anovulation and insulin-treated diabetes mellitus. Am. J. Obstet. Gynecol. 143, 876-882 (1982)
134. G. Reimondo, A. Pia, B. Allasino, F. Tassone, S. Bovio, G. Borretta, A. Angeli, M. Terzolo, Screening of Cushing's syndrome in adult patients with newly diagnosed diabetes mellitus. Clin. Endocrinol. (Oxf) 67, 225-229 (2007)
135. B. Catargi, V. Rigalleau, A. Poussin, N. Ronci-Chaix, V. Bex, V. Vergnot, H. Gin, P. Roger, A. Tabarin, Occult Cushing's syndrome in type-2 diabetes. J. Clin. Endocrinol. Metab. 88, 5808-5813 (2003)
136. M. Terzolo, G. Reimondo, I. Chiodini, R. Castello, R. Giordano, E. Ciccarelli, P. Limone, C. Crivellaro, I. Martinelli, M. Montini, O. Disoteo, B. Ambrosi, R. Lanzi, M. Arosio, S. Senni, A. Balestrieri, E. Solaroli, B. Madeo, R. De Giovanni, F. Strollo, R. Battista, A. Scorsone, V.A. Giagulli, D. Collura, A. Scillitani, R. Cozzi, M. Faustini-Fustini, A. Pia, R. Rinaldi, B. Allasino, G. Peraga, F. Tassone, P. Garofalo, E. Papini, G. Borretta, Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J. Clin. Endocrinol. Metab. 97, 3467-3475 (2012)
137. I. Chiodini, M. Torlontano, A. Scillitani, M. Arosio, S. Bacci, S. Di Lembo, P. Epaminonda, G. Augello, R. Enrini, B. Ambrosi, G. Adda, V. Trischitta, Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur. J. Endocrinol. 153, 837-844 (2005)
138. R. Pasquali, S. Cantobelli, F. Casimirri, M. Capelli, L. Bortoluzzi, R. Flamia, A.M. Labate, L. Barbara, The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J. Clin. Endocrinol. Metab. 77, 341-346 (1993)
139. R. Rosmond, M.F. Dallman, P. Björntorp, Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J. Clin. Endocrinol. Metab. 83, 1853-1859 (1998)
140. E. Torrecilla, G. Fernández-Vázquez, D. Vicent, F. Sánchez-Franco, A. Barabash, L. Cabrerizo, A. Sánchez-Pernaute, A.J. Torres, M.A. Rubio, Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes. Surg. 22, 478-486 (2012)
141. V. Vicennati, R. Pasquali, Abnormalities of the hypothalamic-pituitary- adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration. J. Clin. Endocrinol. Metab. 85, 4093-4098 (2000)
142. T. Reinehr, W. Andler, Cortisol and its relation to insulin resistance before and after weight loss in obese children. Horm. Res. 62, 107-112 (2004)
143. D.J. Wake, E. Rask, D.E. Livingstone, S. Söderberg, T. Olsson, B.R. Walker, Local and systemic impact of transcriptional upregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 88, 3983-3988 (2003)
144. C. Wang, G. Jackson, T.H. Jones, A.M. Matsumoto, A. Nehra, M.A. Perelman, R.S. Swerdloff, A. Traish, M. Zitzmann, G. Cunningham, Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 34, 1669-1675 (2011)
145. S. Wei, M.D. Schmidt, T. Dwyer, R.J. Norman, A.J. Venn, Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin. Obesity (Silver Spring). 17, 1070-1076 (2009)
146. V. Vicennati, L. Ceroni, S. Genghini, L. Patton, U. Pagotto, R. Pasquali, Sex difference in the relationship between the hypothalamic-pituitary-adrenal axis and sex hormones in obesity. Obesity (Silver Spring). 14, 235-243 (2006)
147. C.K. Buffington, J.R. Givens, A.E. Kitabchi, Enhanced adrenocortical activity as a contributing factor to diabetes in hyperandrogenic women. Metabolism 43, 584-590 (1994)
148. T. Grimmichová, J. Vrbíková, P. Matucha, K. Vondra, P.P. Veldhuis, M.L. Johnson, Fasting insulin pulsatile secretion in lean women with polycystic ovary syndrome. Physiol. Res. 57(Suppl 1), 91-98 (2008)
149. M. Hollingdal, C.B. Juhl, R. Dall, J. Sturis, J.D. Veldhuis, O. Schmitz, N. Pørksen, Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia 45, 49-55 (2002)
150. M. Zarković, J. Cirić, Z. Penezić, B. Trbojević, M. Drezgić, Temporal coupling of luteinizing hormone and follicle stimulating hormone secretion in polycystic ovary syndrome. Gynecol. Endocrinol. 15, 381-388 (2001)
151. R. Pascualy, Sleep apnea and type 2 diabetes. A vicious circle. Diabetes Self. Manag. 24, 29-30 (2007)
152. G. Copinschi, Metabolic and endocrine effects of sleep deprivation. Essent. Psychopharmacol. 6, 341-347 (2005)
153. J.C. Lam, C.S. Yan, A.Y. Lai, S. Tam, D.Y. Fong, B. Lam, M.S. Ip, Determinants of daytime blood pressure in relation to obstructive sleep apnea in men. Lung 187, 291-298 (2009)
154. C. Parlapiano, M.C. Borgia, A. Minni, N. Alessandri, I. Basal, M. Saponara, Cortisol circadian rhythm and 24-hour Holter arterial pressure in OSAS patients. Endocr. Res. 31, 371-374 (2005)
155. P.P. Roy-Byrne, T.W. Uhde, R.M. Post, W. Gallucci, G.P. Chrousos, P.W. Gold, The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am. J. Psychiatry 143, 896-899 (1986)
156. D.H. Avery, T.B. Osgood, D.M. Ishiki, L.G. Wilson, M. Kenny, D.L. Dunner, The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder. Am. J. Psychiatry 142, 844-848 (1985)
157. R.G. Kathol, R. Anton, R. Noyes, T. Gehris, Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol. Psychiatry 25, 873-878 (1989)
158. R.G. Kathol, R. Noyes Jr, A.L. Lopez, J.H. Reich, Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia. Psychiatry Res. 24, 211-221 (1988)
159. P. Westberg, K. Modigh, P. Lisjö, E. Eriksson, Higher post-dexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients. Biol. Psychiatry 30, 247-256 (1991)
160. B. Bandelow, D. Wedekind, V. Sandvoss, A. Broocks, G. Hajak, J. Pauls, H. Peter, E. Rüther, Diurnal variation of cortisol in panic disorder. Psychiatry Res. 95, 245-250 (2000)
161. J.L. Abelson, G.C. Curtis, Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch. Gen. Psychiatry 53, 323-331 (1996)
162. National Collaborating Centre for Mental Health (UK) Generalised Anxiety Disorder in Adults.: Management in Primary, Secondary and Community Care. pp 19. London: Royal College of Psychiatrists (2011)
163. E.E. Schweizer, C.M. Swenson, A. Winokur, K. Rickels, G. Maislin, The dexamethasone suppression test in generalised anxiety disorder. Br. J. Psychiatry 149, 320-322 (1986)
164. R.C. Mantella, M.A. Butters, J.A. Amico, S. Mazumdar, B.L. Rollman, A.E. Begley, C.F. Reynolds, E.J. Lenze, Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology 33, 773-781 (2008)
165. S.A. Vreeburg, F.G. Zitman, J. van Pelt, R.H. Derijk, J.C. Verhagen, R. van Dyck, W.J. Hoogendijk, J.H. Smit, B.W. Penninx, Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom. Med. 72, 340-347 (2010)
166. A. Pan, E.S. Schernhammer, Q. Sun, F.B. Hu, Rotating night shift work and risk of type 2 diabetes: two prospective cohort studies in women. PLoS Med (2011). doi:10.1371/journal.pmed.1001141
167. L. Manenschijn, R.G. van Kruysbergen, F.H. de Jong, J.W. Koper, E.F. van Rossum, Shift work at young age is associated with elevated long-term cortisol levels and body mass index. J. Clin. Endocrinol. Metab. 96, 1862-1865 (2011)
168. H. Raff, H. Trivedi, Circadian rhythm of salivary cortisol, plasma cortisol, and plasma ACTH in end-stage renal disease. Endocr. Connect. 19, 23-31 (2012)
169. K. Carlström, A. Pousette, R. Stege, A. Lindholm, Serum hormone levels in men with end stage renal disease. Scand. J. Urol. Nephrol. 24, 75-78 (1990)
170. F. Hammer, N.C. Edwards, B.A. Hughes, R.P. Steeds, C.J. Ferro, J.N. Townend, P.M. Stewart, The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clin. Endocrinol. (Oxf) 73, 566-572 (2010)
171. M. Walser, S. Hill, Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure. Am. J. Kidney Dis. 29, 503-513 (1997)
172. S.H. Shah, L.K. Newby, C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev. 11, 169-179 (2003)
173. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, L.L. Hamm, P.A. McCullough, B.L. Kasiske, E. Kelepouris, M.J. Klag, P. Parfrey, M. Pfeffer, L. Raij, D.J. Spinosa, P.W. Wilson, American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention: kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 42, 1050-1065 (2003)
174. B.J. Carroll, A. Iranmanesh, D.M. Keenan, F. Cassidy, W.H. Wilson, J.D. Veldhuis, Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback. Acta Psychiatr. Scand. 125, 478-491 (2012)
175. J. Licinio, M.L. Wong, P.W. Gold, The hypothalamic-pituitary-adrenal axis in anorexia nervosa. Psychiatry Res. 62, 75-83 (1996)
176. G.S. Birketvedt, E. Drivenes, I. Agledahl, J. Sundsfjord, R. Olstad, J.R. Florholmen, Bulimia nervosa: a primary defect in the hypothalamic-pituitary- adrenal axis? Appetite 46, 164-167 (2006)
177. T.P. Beresford, D.B. Arciniegas, J. Alfers, L. Clapp, B. Martin, H.F. Beresford, Y. Du, D. Liu, D. Shen, C. Davatzikos, M.L. Laudenslager, Hypercortisolism in alcohol dependence and its relation to hippocampal volume loss. J. Stud. Alcohol 67, 861-867 (2006)
178. A. Smals, P. Kloppenborg, Alcohol-induced pseudo-Cushings syndrome. Lancet 1, 1369 (1977)
179. R.H. Stimson, R. Andrew, N.C. McAvoy, D. Tripathi, P.C. Hayes, B.R. Walker, Increased whole-body and sustained liver cortisol regeneration by 11 beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes 60, 720-725 (2011)
180. R. Pasquali, V. Vicennati, Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int. J. Obes. Relat. Metab. Disord. 24(Suppl 2), 47-49 (2000)
181. R. Pasquali, V. Vicennati, A. Gambineri, Adrenal and gonadal function in obesity. J. Endocrinol. Invest. 25, 893-898 (2002)
182. B.R. Walker, R. Andrew, Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann. N. Y. Acad. Sci. 1083, 165-184 (2006)
183. R. Desbriere, V. Vuaroqueaux, V. Achard, S. Boullu-Ciocca, M. Labuhn, A. Dutour, M. Grino, 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 14, 794-798 (2006)
184. T. Tsilchorozidou, J.W. Honour, G.S. Conway, Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5 alpha-reduction but not the elevated adrenal steroid production rates. J. Clin. Endocrinol. Metab. 88, 5907-5913 (2003)
185. F. Roelfsema, P. Kok, A.M. Pereira, H. Pijl, Cortisol production rate is similarly elevated in obese women with or without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95, 3318-3324 (2010)
186. A. Gambineri, G. Forlani, A. Munarini, F. Tomassoni, G.E. Cognigni, W. Ciampaglia, U. Pagotto, B.R. Walker, R. Pasquali, Increased clearance of cortisol by 5 beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. J. Endocrinol. Invest. 32, 210-218 (2009)
187. L.M. Tomfohr, K.M. Edwards, J.E. Dimsdale, Is obstructive sleep apnea associated with cortisol levels? A systematic review of the research evidence. Sleep Med. Rev. 16, 243-249 (2012)
188. T.M. Buckley, A.F. Schatzberg, On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J. Clin. Endocrinol. Metab. 90, 3106-3114 (2005)
189. M. Clodi, M. Riedl, S. Schmaldienst, A. Vychytil, H. Kotzmann, A. Kaider, C. Bieglmayer, G. Mayer, W. Waldhäusl, A. Luger, Adrenal function in patients with chronic renal failure. Am. J. Kidney Dis. 32, 52-55 (1998)